Multiple myeloma trials in France

In France 92 Also abroad 703

92 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in France
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Avignon, Nantes, Nice, Tours, Vandœuvre-lès-Nancy
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
No phaseNot yet taking people in France
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
Where
Pierre-Bénite
Age
18 years and over
People
100
Run by
Hospices Civils de Lyon
See details and how to joinNCT07721350
Phase 1Taking people
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.
Where
Angers, Brest, Caen Cedex 9, Nantes Cedex 1, Tours
Age
18 years and over
People
35
Run by
Centre Hospitalier Universitaire De Nantes
See details and how to join2024-515219-23-00 · EU 2024-515219-23-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Montpellier Cedex 5, Nantes, Paris, Poitiers, Toulouse
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
Phase 2Taking people
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
Where
Amiens Cedex 1, Angers, Bayonne, Besancon Cedex, Caen Cedex 9, Clamart, Clermont-Ferrand, Compiegne, Créteil Cedex, Dijon, Epagny Metz-tessy, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Libourne Cedex, Limoges, Lorient, Lyon, Marseille, Nantes, Nice, Nimes Cedex 9, Paris, Périgueux, Perpignan Cedex, Pessac Cedex, Poitiers, Quimper Cedex, Saint-Malo Cedex, Saint Nazaire Cedex, Strasbourg, Tarbes Cedex 9, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy Cedex, Vannes
Age
18 years and over
People
176
Run by
Centre Hospitalier Universitaire De Nantes
See details and how to join2024-517325-43-00 · EU 2024-517325-43-00
Phase 2Taking people
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Where
Poitiers, Saint-Cloud
Age
18 years and over
People
116 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Paris, Paris Cedex 12, Pierre-Bénite
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Bordeaux, Villejuif
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
No phaseTaking people
Prospective Cohort With Hemopathy in Languedoc-Roussillon
Where
Montpellier
Age
18 years and over
People
500
Run by
University Hospital, Montpellier
See details and how to joinNCT02134574
No phaseTaking people
Evaluation of Skin Tests in Biotherapy Allergies
Where
Angers
Age
18 years and over
People
70
Run by
University Hospital, Angers
See details and how to joinNCT06971848
No phaseTaking people
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
Where
Épagny, Grenoble, Lyon, Montpellier, Saint-Etienne, Villefranche-sur-Saône
Age
18 years to 70 years
People
204
Run by
Centre Leon Berard
See details and how to joinNCT05947136
No phaseTaking people
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Where
Rouen
Age
18 years and over
People
300
Run by
University Hospital, Rouen
See details and how to joinNCT06559033
Phase 1Taking people
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Lille Cedex, Marseille, Nice, Toulouse Cedex 9, Tours
Age
18 years and over
People
135 worldwide
Run by
AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00
No phaseTaking people
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Where
Toulouse
Age
18 years and over
People
2,000
Run by
University Hospital, Toulouse
See details and how to joinNCT04888039
No phaseTaking people
Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma
Where
Annecy, Chambéry
Age
61 years and over
People
86
Run by
Centre Hospitalier Metropole Savoie
See details and how to joinNCT07547007
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Bobigny, Limoges Cedex 1, Nantes Cedex 2, Villejuif
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 2Not yet taking people in France
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Avignon Cedex 9, Bayonne, Creteil Cedex, La Roche Sur Yon Cedex 9, Lille Cedex, Montpellier Cedex 5, Nantes, Nantes Cedex 2, Paris, Pessac, Poitiers, Toulouse, Tours Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
70
Run by
Assistance Publique Hopitaux De Paris
See details and how to join2025-521090-14-00 · EU 2025-521090-14-00
Phase 1Taking people
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Where
Lille, Nantes, Paris Cedex 12, Paris Cedex 13, Poitiers
Age
18 years and over
People
200 worldwide
Run by
Ichnos Sciences SA
See details and how to joinNCT05862012 · EU 2023-507071-21-01
Phase 1Taking people
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Where
Lille, Nantes
Age
18 years and over
People
87 worldwide
Run by
Sanofi
See details and how to joinNCT06630806
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Angers, Bobigny, Le Mans, Lille, Limoges, Lyon, Marseille, Nantes, Nice, Paris, Talence, Villejuif
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
No phaseNot yet taking people in France
Multiple Myeloma Extramedulary Disease Samples FFPE
Where
Lyon 06
Age
18 years and over
People
15
Run by
BIWAKO
See details and how to joinNCT07354555
No phaseNot yet taking people in France
Multiple Myeloma t(4 ;14) FFPE Samples
Where
Lyon
Age
18 years and over
People
20
Run by
BIWAKO
See details and how to joinNCT07482761
Phase 1Taking people
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Paris
Age
18 years and over
People
187 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06153251 · EU 2023-506003-26-00
No phaseTaking people
Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment
Where
Avignon
Age
18 years and over
People
120
Run by
Centre Hospitalier Henri Duffaut - Avignon
See details and how to joinNCT06789003
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Dijon, Nantes, Orléans, Pessac, Salouël
Age
18 years and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757